Why am I interested in NKTR?
As you can tell from my profile and background, I am NOT an experienced pharma stock investor or analyst. My expertise is in B2B software and high technology. However, several close friends who are physicians had recently been making a lot of "noise" to me about a company called Nektar Therapeutics (NASDAQ:NKTR). These are some of the top physicians in their respective fields, so I take whatever they say about drugs and medicine very seriously. Before investing, however, I had to do my own, deep research into NKTR to understand the potential. I am going to boil it down for you in very simple terms that anyone can grasp. What I learned in my research was absolutely incredible and exciting. In my layman's opinion there is HUGE upside potential in Nektar Therapeutics. It's just common sense.
Background on Nektar Therapeutics
The company was founded in 1990 and appears to owe most of its commercial success and promise to a proprietary technique to enhance the efficacy of other drugs. The technique is called PEGylation. Now to be clear, how the thing works is WAY above my pay grade. All I can tell you is that a whole lot of other drug companies have partnered or co-invested with Nektar to develop or enhance drugs using this technique, including Pfizer back in 2004 for an Insulin drug. I'm not even sure where the IP originated, but Nektar now owns the rights to it due to some patent litigation it settled back in 2006. So whether Nektar invented PEGylation or not, they now have exclusive rights to it. This exclusivity, it turns out, is a pretty big deal, as we'll see in a moment.
NKTR Stock Explodes to over $100
Back in late 2017, Nektar Therapeutics and Bristol-Myers Squibb (
